Get the Stockscreener App
27.85
0.89%
-0.25
Pre-market:
27.85
Roivant Sciences Ltd stock is traded at $27.85, with a volume of 6.14M.
It is down -0.89% in the last 24 hours and up +26.76% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$28.10
Open:
$27.33
24h Volume:
6.14M
Relative Volume:
0.90
Market Cap:
$19.93B
Revenue:
$125.68M
Net Income/Loss:
$4.81B
P/E Ratio:
4.9292
EPS:
5.65
Net Cash Flow:
$-781.21M
1W Performance:
-1.45%
1M Performance:
+26.76%
6M Performance:
+121.21%
1Y Performance:
+173.84%
1-Day Range:
$26.94
$28.24
1-Week Range:
$26.94
$29.20
52-Week Range:
$8.73
$29.20
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
27.85 | 20.11B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-02-25 | Initiated | Citigroup | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Roivant's Priovant Says FDA Accepts Application With Priority Review for Dermatomyositis Treatment - marketscreener.com
Roivant Sciences receives FDA priority review for dermatomyositis drug By Investing.com - Investing.com Australia
Roivant Sciences receives FDA priority review for dermatomyositis drug - Investing.com
FDA to weigh first targeted therapy for debilitating dermatomyositis - Stock Titan
Roivant Sciences Ltd. $ROIV Position Lowered by Rafferty Asset Management LLC - MarketBeat
Roivant Sciences Ltd. (ROIV) Stock Analysis: Impressive Growth Potential Amidst Innovative Biotechnology Advances - DirectorsTalk Interviews
Anfield Capital Management LLC Buys Shares of 155,644 Roivant Sciences Ltd. $ROIV - MarketBeat
Fox Run Management L.L.C. Invests $877,000 in Roivant Sciences Ltd. $ROIV - MarketBeat
Liquidity Mapping Around (ROIV) Price Events - Stock Traders Daily
IPO Launch: Can Roivant Sciences Ltd outperform under higher oil pricesMarket Performance Report & Weekly Top Performers Watchlists - baoquankhu1.vn
Analyst Downgrade: What is the dividend yield of Roivant Sciences LtdJuly 2025 Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Vanguard Group Inc. Has $587.12 Million Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences stock hits all-time high at 27.95 USD - Investing.com India
Roivant Sciences (ROIV) Price Target Increased by 18.98% to 32.44 - Nasdaq
Roivant Sciences stock hits all-time high at 27.95 USD By Investing.com - Investing.com Canada
Support Test: Should I hold or sell Roivant Sciences Ltd nowMarket Performance Summary & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Roivant Sciences (NASDAQ:ROIV) Sets New 52-Week HighShould You Buy? - MarketBeat
Roivant Sciences Insider Sold Shares Worth $82,039,460, According to a Recent SEC Filing - marketscreener.com
Roivant Sciences (NASDAQ:ROIV) Insider Sells $27,492,361.50 in Stock - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Insider Sells $16,159,098.90 in Stock - MarketBeat
Insider Selling: Roivant Sciences (NASDAQ:ROIV) Insider Sells 1,400,000 Shares of Stock - MarketBeat
Aug Chart Watch: What is the dividend yield of Roivant Sciences LtdTreasury Yields & Reliable Trade Execution Plans - baoquankhu1.vn
Roivant Sciences Ltd. (ROIV) Investor Outlook: Analyzing Its 16.86% Potential Upside - DirectorsTalk Interviews
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - AOL.com
Published on: 2026-02-21 23:52:14 - baoquankhu1.vn
CenterBook Partners LP Grows Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Eric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Eric Venker of Roivant Sciences (ROIV) exercises options and sells 200,000 shares - Stock Titan
Risk Off: Can Veracyte Inc ride the EV waveQuarterly Profit Summary & Weekly Return Optimization Alerts - baoquankhu1.vn
Why Roivant Sciences Ltd. (87S) stock appeals to dividend investorsTrade Ideas & Long-Term Growth Plans - mfd.ru
Roivant Sciences Ltd. (ROIV) Stock Analysis: Assessing the 19.95% Potential Upside Amidst Biotech Innovations - DirectorsTalk Interviews
Why (ROIV) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Roivant Sciences Advances PHocus Trial Milestone As Shares Trade Below Targets - simplywall.st
Roivant Sciences PHocus Trial Milestone Highlights Pipeline Progress And Valuation Gap - Yahoo Finance
Momentum Shift: Is Roivant Sciences Ltd backed by strong institutional buying2025 Growth vs Value & Short-Term Trading Alerts - baoquankhu1.vn
Is Roivant Sciences Ltd. stock a contrarian buyJuly 2025 Trade Ideas & Weekly High Return Forecasts - mfd.ru
Roivant Sciences Advances PH Programs As Investors Weigh Pipeline Milestones - simplywall.st
Citi raises Roivant Sciences (ROIV) PT to $35 following positive phase 2 brepocitinib data - MSN
Citi Raises Roivant Sciences (ROIV) PT to $35 Following Positive Phase 2 Brepocitinib Data - Insider Monkey
Insider Selling: Roivant Sciences (NASDAQ:ROIV) Director Sells 375,784 Shares of Stock - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Director Daniel Allen Gold Sells 425,000 Shares - MarketBeat
Healthcare REIT Posts 16.4% NOI Growth as Shares Soar 93%: Why This Fund's New Stake Stands Out - The Motley Fool
HC Wainwright Analysts Increase Earnings Estimates for ROIV - MarketBeat
Is Roivant Sciences Ltd. stock undervalued right now2025 Short Interest & AI Based Buy and Sell Signals - mfd.ru
TD Cowen remains bullish on Roivant Sciences Ltd. (ROIV) – here’s why - MSN
Can Roivant Sciences Ltd. lead its sector in growthLayoff News & Detailed Earnings Play Alerts - mfd.ru
Roivant Sciences (NASDAQ:ROIV) Insider Sells $8,985,003.27 in Stock - MarketBeat
Impax Asset Management Group plc Sells 200,000 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences stock price target raised to $38 from $36 at Goldman Sachs - Investing.com Australia
Candriam S.C.A. Increases Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences stock price target raised to $33 from $26 at H.C. Wainwright - Investing.com Australia
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.71%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):